Boston, MA 02/07/2013 (wallstreetpr) – Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rose by 11.66 percent to close at $19.53 on Monday. The shares recorded an intraday high of $20.26 per share and an intraday low of $18.10 per share during the day. As of the last trading session, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) had a 52-week high of $25.40 and a 52-week low price of $15.35 per share.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was trading on Monday at very high volumes, namely at 5.08 million shares, while the average level of trading volume in the company is only 2.57 million shares per day. With 184.69 million shares outstanding in the market, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) currently has a market cap of $3.61 billion and an institutional ownership of 84 percent of total capital.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is a biopharmaceutical company operating in the international markets, and is primarily engaged in the development and commercialization of anticancer drugs. The first medicine of the oncology-based pharmaceutical company, Iclusig, has been approved by the Food and Drug Administration of the United States for the use in the treatment of chronic, accelerated or blast phase chronic myeloid leukemia in adult patients.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is also involved in conducting additional clinical trials for the application of Iclusig regarding the treatment of other forms of cancer. Furthermore, the biopharmaceutical company started in early January 2013 the research on the use of another drug, AP26113, for the treatment of certain forms of lung cancer. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is expected to release its quarterly earnings reports by the end of July 2013 and the expectations are high with regards to the financial performance of the oncology-based pharmaceutical company.
